ARS Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 80 to 84.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an 80 or higher RS Rating as they begin their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
While ARS Pharmaceuticals is not near a proper buy point right now, see if it goes on to form and break out of a proper consolidation.
ARS Pharmaceuticals showed 0% earnings growth in the latest quarterly report. Revenue rose 4,900%.
The company holds the No. 213 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
